Treatment Protocol for Hemophagocytic Lymphohistiocytosis 2004
This trial is active, not recruiting.
|Treatments||dexamethasone, etoposide, cyclosporin, intrathecal therapy, stem cell transplant|
|Sponsor||Karolinska University Hospital|
|Collaborator||Azienda Ospedaliero, Universitaria Meyer|
|Start date||January 2004|
|End date||December 2011|
|Trial size||300 participants|
|Trial identifier||NCT00426101, HLH-2004|
Without therapy HLH is often fatal, and often rapidly fatal. The treatment protocol HLH-94 has improved survival markedly as compared to the survival earlier. We now aim to improve survival further.
|Endpoint classification||efficacy study|
|Intervention model||single group assignment|
time frame: 1-year after diagnosis
time frame: 5-years after diagnosis
Male or female participants up to 18 years old.
Inclusion Criteria: - Patients who fulfil the diagnostic criteria of HLH. Exclusion Criteria: - Prior cytotoxic or cyclosporin treatment for HLH.
|Official title||HLH-2004 Treatment Protocol|
|Principal investigator||Jan-Inge Henter, MD, PhD|
|Description||The most dangerous period after HLH diagnosis is the first 2 months. In HLH-2004 we provide additional therapy during this period as compared to in HLH-94.|
Call for more information